1. Глинкина И.В. Результаты наблюдательной программы по применению инсулина гларгин (Лантус) в комбинации с пероральными сахароснижающими препаратами или прандиальными инсулинами для лечения сахарного диабета 2-го типа в повседневной клинической практике. Проблемы эндокринологии. 2010; 5 (10): 61–6.
2. Залевская А.Г., Вербовая Н.И., Родионова Т.И., Викулова О.К., Шестакова М.В. Базальная инсулинотерапия у пациентов с сахарным диабетом 2 типа с неудовлетворительным контролем гликемии на пероральной сахароснижающей терапии: результаты прямого сравнительного исследования аналогов инсулина Лантус и Левемир. Сахарный диабет. 2010; 2: 106–12.
3. Шишкова Ю.А., Суркова Е.В., Мотовилин О.Г., Майоров А.Ю. Качество жизни при сахарном диабете: определение понятия, современные подходы к оценке, инструменты для исследования (обзор литературы). Сахарный диабет. 2011; 3: 70–5.
4. Abrahamson MJ. Basal insulins: Pharmacological properties and patient perspectives. Primary Care Diabetes 2010; 4 (Suppl. 1): S19–S23.
5. Barnett A. Dosing of insulin glargine in the treatment of type 2 diabetes. Clin Ther 2007; 29: 987–99.
6. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus- present and future perspectives. Nat Rev Endocrinol 2012; 8: 228–36.
7. Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes. 2013; 6: 327–38.
8. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (2): 233–40.
9. Davies M, Storms F, Shutler S et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28 (6): 1282–8.
10. DeWitt DE, Hirch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289 (17): 2254–64.
11. Eliaschewitz FG, Calvo C, Valbuena H et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006; 37 (4): 495–501.
12. Evans ML, Sharplin P, Owens DR et al. Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. Br J Diabetes&Vasc Dis 2010; 10 (4): 178–82.
13. Gwaltney C, Martin ML, Gruenberger JB. Type 2 Diabetes patient perspectives on hupoglycemia. Value in Health 2010; 13 (7): A297.
14. Hanefeld M, Fleischmann H, Landgraf W, Pistrosch F. EARLY Study: early basal insulin therapy under real-life conditions in type 2 diabetics. Diabetes, Stoffwechsel und Herz 2012; 2: 91–7.
15. Hirsch IrlB., Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 2 (23): 78–86.
16. Holz B, Schroder-Bernardi D, Kostev K. Prevalence and outcome of insulin analogue treatment comparing Germany, UK, and France. Value in Health 2010; 13 (7): A285.
17. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52 (12): 2499–506.
18. Joshi S, Joshi P. A review of insulin and insulin regimens in type 2 diabetes SA. Fam Pract 2009; 51 (2): 97–102.
19. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49 (12): 2142–8.
20. Neumiller JJ, Odegard PS, Wysham CH. Update on insulin management in type 2 diabetes. Diabetes Spectrum 2009; 22: 85–91.
21. ORIGIN Trial Investigators, Gerstein H et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367 (4): 319–28.
22. Pfohl M, Dippel FW, Kostev K et al. Different persistence on initial basal supported oral therapy in type 2 diabetics is associated with unequal distributions of insulin treatment regimens under real-life conditions in Germany. Int J Clin Pharmacol Ther 2010; 48 (11): 761–6.
23. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005; 28 (5): 1107–12.
24. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6.
25. Robertson C. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control. Diabetes Educator 2006; 32 (3): 423–32.
26. Rosenstock J, Davies М, Ноmе P et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51 (3): 408–16.
27. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12 216 patients. Diabetes Obes Metab 2007; 9: 31–8.
28. Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational program on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006; 22 (2): 335–41.
29. Shim WS, Kim SK, Kim HJ. Decremental of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006; 155 (4): 615–22.
30. Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180 (4): 385–97.
31. Stumvoll M, Goldstein BJ, van Haeften TW. Pathogenesis of type 2 diabetes. Endocr Res 2007; 32: 19–37.
32. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–51.
33. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352 (9131): 837-53.
34. Wajchenberg BL. b-cell failure in diabetes and preservation by clinical treatment. Endocrine Rev 2007; 28: 187–218.
35. Weng J, Li Y, Xuet W et al. Effect of intensive insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371: 1753–60.
36. Jr White JR, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med 1997; 101 (2): 58–70.

Е.В.Бирюкова

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России